Get the Stockscreener App
88.17
3.36%
2.87
Pre-market:
88.11
-0.06
-0.07%
Vaxcyte Inc stock is traded at $88.17, with a volume of 1.81M.
It is up +3.36% in the last 24 hours and up +1.90% over the past month.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-A1, and VAX-PG.
See More
Previous Close:
$85.30
Open:
$86.06
24h Volume:
1.81M
Relative Volume:
1.59
Market Cap:
$10.99B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-19.17
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
+12.84%
1M Performance:
+1.90%
6M Performance:
+8.01%
1Y Performance:
+45.57%
1-Day Range:
$85.24
$88.54
1-Week Range:
$80.30
$90.06
52-Week Range:
$58.10
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
88.17 | 10.99B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
CARGO Therapeutics, Inc. Enters into Sublease Agreement with Vaxcyte, Inc -July 08, 2024 at 04:18 pm EDT - Marketscreener.com
Vaxcyte Catapults As It Looks To Take On Pfizer, Merck In A Massive Market - MSN
Why Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts? - Insider Monkey
Vaxcyte (NASDAQ:PCVX) Trading Up 7.8%Should You Buy? - MarketBeat
Teri Loxam Sells 6,250 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - MarketBeat
Alexandria Announces Long-Term Lease at San Carlos Mega Campus - MSN
Learn to Evaluate (PCVX) using the Charts - Stock Traders Daily
Vaxcyte (NASDAQ:PCVX) Stock Price Up 7.8%Here's What Happened - MarketBeat
Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy (NASDAQ:PCVX) - Seeking Alpha
Leerink Partnrs Forecasts Vaxcyte FY2029 Earnings - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Harbor Capital Advisors Inc. - MarketBeat
Diversified Trust Co Acquires New Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte's SVP Mikhail Eydelman sells $427,922 in stock - Investing.com India
Vaxcyte's SVP Mikhail Eydelman sells $427,922 in stock By Investing.com - Investing.com Canada
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm - The Malaysian Reserve
Long Term Trading Analysis for (PCVX) - Stock Traders Daily
Brokerages Set Vaxcyte, Inc. (NASDAQ:PCVX) Target Price at $145.71 - MarketBeat
Vaxcyte COO Jim Wassil sells shares valued at $669,266 By Investing.com - Investing.com Australia
Jim Wassil Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock - MarketBeat
Vaxcyte COO Jim Wassil sells shares valued at $669,266 - Investing.com
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Principal Financial Group Inc. - MarketBeat
Trump and Interest Rates: The 2 Key Reasons This Vanguard ETF Could Thrive in 2025 - The Motley Fool
Vaxcyte (NASDAQ:PCVX) Trading Down 5.8%Here's What Happened - MarketBeat
When (PCVX) Moves Investors should Listen - Stock Traders Daily
Is Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024? - MSN
10 Best Performing Biotech Stocks in 2024 - Insider Monkey
Vaxcyte stock supported by Goldman Sachs for addressing next-gen vaccine challenges - Investing.com Canada
Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset - MSN
Vaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia asset (PCVX:NASDAQ) - Seeking Alpha
Vaxcyte (NASDAQ:PCVX) Coverage Initiated at The Goldman Sachs Group - MarketBeat
Vaxcyte's president and CFO sells $710,248 in stock transactions - Investing.com India
Vaxcyte's president and CFO sells $710,248 in stock transactions By Investing.com - Investing.com Canada
Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of Stock - MarketBeat
Vaxcyte’s president and CFO sells $710,248 in stock transactions By Investing.com - Investing.com Nigeria
(PCVX) Investment Report - Stock Traders Daily
Lord Abbett & CO. LLC Raises Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Franklin Resources Inc. Raises Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Geode Capital Management LLC Buys 259,010 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Receives $147.50 Average Price Target from Analysts - MarketBeat
Applied Industrial Technologies (AIT-N) QuotePress Release - The Globe and Mail
Merck & Company (MRK-N) QuotePress Release - The Globe and Mail
Why Wall Street Rates These 2 Russell 2000 Stocks a “Strong Buy” - MSN
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):